Core Viewpoint - The company is facing challenges in maintaining its market value despite strong operational performance and growth, with significant concerns raised by investors regarding its stock price and market positioning compared to competitors [2][4]. Company Performance - As of September 22, 2025, the company's stock price closed at 9.47 yuan, down 0.73%, with a trading volume of 40,400 shares and a turnover of 38.26 million yuan [1]. - The company has been compared unfavorably to competitors, with its market capitalization significantly lower than that of peers like Zhend Medical and Sturdy Medical, which have market values approximately 2 to 5 times greater [4]. M&A Strategy - The company has indicated that its future merger and acquisition (M&A) focus will be on the health industry, emphasizing the importance of synergy and industry integration [2][3]. - The management has acknowledged the high risks associated with M&A activities and has adopted a cautious approach towards potential acquisitions [2]. Market Sentiment - Investor sentiment is currently negative, with concerns about the company's declining stock price despite its strong performance and generous dividend distribution over the years [2][4]. - On September 22, 2025, there was a net outflow of 1.19 million yuan from institutional investors, while retail investors contributed a net inflow of 6.11 million yuan [4].